Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas by Schindlbeck, Christian et al.
Open Access
Available online http://breast-cancer-research.com/content/7/6/R1174
R1174
Vol 7 No 6 Research article
Prognostic relevance of disseminated tumor cells in the bone 
marrow and biological factors of 265 primary breast carcinomas
Christian Schindlbeck1, Theresa Kampik1, Wolfgang Janni1, Brigitte Rack1, Udo Jeschke1, 
Stan Krajewski2, Harald Sommer1 and Klaus Friese1
11st Department of Obstetrics and Gynecology Klinikum, Ludwig-Maximilians-University, D-80337 Munich, Germany
2Burnham Institute, La Jolla, California 92037-1062, USA
Corresponding author: Christian Schindlbeck, Christian.Schindlbeck@med.uni-muenchen.de
Received: 31 Jul 2005 Revisions requested: 6 Sep 2005 Revisions received: 4 Oct 2005 Accepted: 28 Oct 2005 Published: 24 Nov 2005
Breast Cancer Research 2005, 7:R1174-R1185 (DOI 10.1186/bcr1360)
This article is online at: http://breast-cancer-research.com/content/7/6/R1174
© 2005 Schindlbeck et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction The prognostic significance of disseminated tumor
cells in the bone marrow (DTC-BM) of breast cancer patients
has been demonstrated in many studies. Yet, it is not clear
which of the primary tumors' biological factors predict
hematogenous dissemination. We therefore examined 'tissue
micro arrays' (TMAs) of 265 primary breast carcinomas from
patients with known bone marrow (BM) status for HER2,
Topoisomerase IIα (Top IIa), Ki 67, and p53.
Methods BM analysis was performed by cytospin preparation
and immunocytochemical staining for cytokeratin (CK). TMAs
were examined by immunohistochemistry (IHC) for HER2, Top
IIa, Ki 67 and p53, and fluorescence in situ hybridization (FISH)
for HER2.
Results HER2 (2+/3+) was positive in 35/167 (21%) cases
(FISH 24.3%), Top IIa (>10%) in 87/187 (46%), Ki 67 in 52/
184 (28%) and p53 (>5%) in 61/174 cases (34%). Of 265
patients, 68 (25.7%) showed DTC-BM with a median of 2/2 ×
106 cells (1 to 1,500). None of the examined factors significantly
predicted BM positivity. Significant correlation was seen
between HER2 IHC and Top IIa (p = 0.06), Ki 67 (p = 0.031),
and p53 (p < .001). Top IIa correlated with Ki 67 and p53, and
Ki 67 also with p53 (p = 0.004). After a median follow-up of
60.5 months (7 to 255), the presence of DTC-BM showed
prognostic relevance for overall survival (p = 0.03), whereas
HER2 (IHC, p = 0.04; FISH, p = 0.03) and Ki 67 (p = 0.04)
correlated with disease free survival, and HER2 with distant
disease free survival (IHC, p = 0.06; FISH, p = 0.05).
Discussion The congruence of the examined factors'
expression rates indicates a causal line of suppressor,
proliferation, and mitosis markers, and growth factor receptors.
Hematogenous tumor cell spread seems to be an independent
process. The examination of these factors on DTC-BM is the aim
of ongoing research.
Introduction
In recent years, the view on breast cancer has changed from
that of a more locoregional process towards an early general-
ized disease. The importance of curative local treatment, there-
fore, is decreasing [1] as more and more patients at all stages
receive systemic chemo- or hormone therapy, even when
tumor size is small or lymph node status is negative [2]. The
determination of new prognostic parameters to better discrim-
inate and stratify patients for individualized therapies is the
focus of ongoing research. The presence of disseminated
tumor cells in the bone marrow (DTC-BM) seems to indicate
hematogenous dissemination and proved to be prognostically
significant for the subsequent development of metastases and
tumor associated death in many studies [3-6]. With this new
information, patient subgroups requiring intensified oncologi-
cal care and treatment could be identified.
BM = bone marrow; CMF = cyclophosphamide-methotrexat-fluorouracil; DDFS = distant disease free survival; DFS = disease free survival; DTC = 
disseminated tumor cell; DTC-BM = DTCs in bone marrow; FISH = fluorescence in situ hybridization; HER2 = human epithelial growth factor receptor 
2; IHC = immunohistochemistry; OS = overall survival; PBS = phosphate-buffered saline; SSC = sodium chloride-sodium citrate buffer; TMA = tissue 
micro array; Top IIa = topoisomerase IIα.Breast Cancer Research    Vol 7 No 6    Schindlbeck et al.
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Hematogenous tumor cells appear to spread at all stages of
carcinogenesis [7]. Tumorigenesis, dissemination, aggrega-
tion, and metastasis are very complex processes, probably
involving hundreds of biological factors, and giving rise to the
heterogeneity of tumors. The determination of some of these
factors has shown prognostic impact.
The first several steps of carcinogenesis are characterized by
genetic alterations. An imbalance between tumor promotor
and suppressor genes leads to accelerated mitosis and prolif-
eration. The TP53 tumor suppressor gene, which is located on
chromosome 17, encodes the nuclear protein p53, which reg-
ulates proliferation of normal cells [8]. In malignant tumors, het-
erogenous forms of mutations can be found [9]. Most TP53
mutations result in an accumulation of nonfunctional protein in
the tumor cell nuclei, preventing apoptosis and leading to priv-
ileged growth of the transformed cells. Due to the long half-life
of these proteins, they can be detected by immunohistochem-
ical staining; 20% to 40% of breast carcinomas show muta-
tions of the TP53 gene [10]. Although there is controversy
concerning the most suitable method for determining p53 sta-
tus, many studies revealed that the TP53 gene and associated
protein mutations have a negative prognostic impact for overall
survival [11-13].
Tumor cells are characterized by accelerated mitosis and pro-
liferation. Among several proliferation markers, Ki 67 is evalu-
ated as the most frequent protein in breast cancer. The fact
that the Ki 67 protein is present during all active phases of the
cell cycle (G1, S, G2, and mitosis), but is absent from resting
cells (G0), makes it an excellent marker for determining the
growth fraction within tissues. During interphase, the antigen
can be exclusively detected within the nucleus; alternatively, in
mitosis, most of the protein is relocated to the surface of the
chromosomes. Localization of the Ki 67 protein, as well as dif-
ferent isoforms, could play an important role in cell cycle regu-
lation. Nevertheless, the exact biological function of Ki 67
remains unclear, even 20 years after it was first described
[14]. In many studies, expression of this marker was associ-
ated with reduced disease free and overall survival [15-17] in
breast cancer patients.
Another important factor in mitosis is topoisomerase IIα (Top
IIa). This nuclear enzyme is one of five identified topoisomer-
ases interacting with the cell's double-helix DNA, thus playing
an important role in DNA replication, transcription, recombina-
tion, condensation or segregation [18]. Topoisomerases act
as targets of many antimitotic and antiproliferative drugs,
called topoisomerase inhibitors, of which anthracyclins are the
clinically most important in breast cancer. Top IIa gene ampli-
fication or protein expression is also reported to be a negative
prognostic factor [19] and predictor of mainly anthracyclin
response.
Finally, one of the most prominent biological factors of breast
carcinomas is the human epithelial growth factor receptor 2
(HER2 or cerbB2), which belongs to a family of four charac-
terized subtypes of growth factor receptors. HER2 is a 185
kDa transmembranous protein coded by a gene on the long
arm of chromosome 17. The extracellular segment binds to dif-
ferent ligands while the intracellular section mediates signal
transduction to the nucleus by tyrosine kinase activity. HER2,
a marker of aggressive tumors, promotes accelerated mitosis,
inhibition of apoptosis, neoangiogenesis, tumor cell migration
and invasion [20]. Although the prognostic impact of HER2 is
under discussion, most studies discovered a significant corre-
lation between HER2 overexpression or amplification and
poor survival [21]. Furthermore, HER2 overexpression pre-
dicts a poor response to antihormonal and cyclophospha-
mide-methotrexat-fluorouracil  (CMF) therapy, although a
better response was seen with anthracyclin, taxane and, most
importantly, trastuzumab based treatment [22].
All of the examined factors, when overexpressed, seem to be
associated with tumor aggressiveness and reduced survival. If,
by hypothesis, this reduced survival is partly due to hematog-
enous dissemination, a correlation between these factors of
tumor biology and DTC-BM could be assumed. To investigate
if these biological factors could predict the presence of DTC-
BM, and which of them are correlated with survival data, we
examined the expression and amplification of HER2, Top IIa, Ki
67, and p53 on tissue micro arrays (TMAs) of 265 breast can-
cer patients with known bone marrow (BM) status at the time
of primary diagnosis.
Methods
Patients
All patients who attend the 1st Department of Obstetrics and
Gynecology, Ludwig-Maximilians-University, Munich, Ger-
many, for surgical treatment of breast cancer are offered BM
aspiration for screening of hematogenous tumor cell dissemi-
nation. In addition, patients who come for further chemo- or
radiation therapy after primary surgery from other hospitals are
offered a BM examination. During the follow up visits, repeated
aspirations are proposed in order to monitor the BM status
during the course of the disease. The experimental nature of
this method and the potential side effects are explained to
patients. Futhermore, a written informed consent must have
been completed according to the local ethics committee
guidelines.
If the primary surgery was performed at our hospital, then his-
tological examination was performed at our institute's histopa-
thology laboratory. For comparison of results, the original
patients' files and pathology reports were taken into account.
Histological examination and evaluation was made according
to the TNM classification. Hormone receptor status was exam-
ined immunohistochemically; estrogen receptor positivity was
indicated when the immunoreactive score (IRS) was moreAvailable online http://breast-cancer-research.com/content/7/6/R1174
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than 1. For this study, we evaluated breast cancer patients
who were initially diagnosed by bone marrow examination and
whose paraffin embedded breast cancer tissues had been
archived.
Bone marrow preparation and immunocytochemistry
The procedure of bone marrow aspiration and preparation
used in our laboratory has been described previously [23]. BM
aspiration was performed at both anterior iliac crests (2 to 8
ml each side), either under general anesthesia prior to primary
surgery of breast cancer or under local anesthesia. Samples
were collected in heparinized syringes and processed within
hours. After centrifugation at 900 g for 30 minutes with a
Ficoll-Hypaque (Pharmacia, Freiburg, Germany) density gradi-
ent (1.077 g/mol), mononuclear cells were washed, and 2 ×
106 cells centrifuged onto each glass slide at 150 g for 5 min-
utes. The cytospin slides were dried overnight and then
stained immunocytochemically or frozen at -80°C.
The detection of DTC-BM was achieved by staining with the
monoclonal antibody A45-B/B3 (Micomet, Munich, Germany),
which is directed against common cytokeratin epitopes,
including the cytokeratin heterodimers 8/18 and 8/19. The
concentration used to detect cytokeratin-positive cells in bone
marrow cytospins was 2.0 µg/ml. The specific reaction of the
primary antibody is indicated with the alkaline phosphatase
anti-alkaline phosphatase technique, combined with new
fuchsin staining. For each patient, 2 × 106 cells were screened
manually by bright field microscopy. Because of the absence
of any background staining, we obtained no indeterminate
results. Stained cells were classified as DTC-BM only if they
matched the criteria defined previously [23,24], taking into
account morphological aspects and excluding unspecifically
stained mononuclear cells or cell clusters. All positive results
were evaluated by two independent observers.
The breast cancer cell line BT-20A served as a positive control
for cytokeratin immunostaining. The specificity of the antibody
reaction was tested using an unrelated mouse-myeloma anti-
body (Sigma, Deisenhofen, Germany) for isotype control on
the patients' bone marrow samples, with an identical number
of cells as negative control. Up to now, bone marrow samples
from more than 200 patients without malignant disease have
been examined, with a false positive rate of 1% [25].
Preparation and examination of tissue micro arrays
Paraffin embedded tissue blocks from patients who under-
went BM aspiration at primary diagnosis were picked out for
TMA preparation. Representative tumor areas were either
marked on the blocks or compared with the original hematox-
ylin and eosin (H&E) stained sections.
TMAs were prepared at The Burnham Institute, La Jolla, CA,
USA using the following technique. Small tissue biopsies were
retrieved from selected regions of archived tissue blocks, and
these cylindrical samples (diameter 1.0 mm) from different
tumors subsequently arrayed in a new paraffin block. TMAs
were constructed using a custom-built precision Tissue
Arrayer from Beecher Instruments (Silver Springs, MD, USA).
Five micrometer sections from these TMA blocks can then be
used for analysis by fluorescence in situ hybridisation (FISH)
or immunohistochemistry (IHC). The most important advan-
tages of tissue array technology include increased capacity,
negligible damage caused to the original tissue blocks, the
precise positioning of tissue specimens and the utility of these
tissues in different kinds of molecular analyses. It is possible to
retrieve 15 to 50 punched samples from each donor block
without significantly damaging it.
All TMAs were examined by an independent pathologist on
H&E staining first. After this, analysis was done spot by spot
following the rows and columns. Allocation of the results was
done according to lists provided with the TMAs. For this study,
a median of three cores (one to nine) per case could be eval-
uated. Results for the individual cases were then aggregated
by determining the median of all the single examinations.
Her2, Top IIa, KI 67 and p53 immunohistochemistry
Antibody staining methods were similar for each of the differ-
ent antibodies. The antibodies and methods of evaluation are
summarized in Table 1. In general, slides were deparaffinated
in xylol, dehydrated, and endogenuous peroxidase blocked
with H2O2 in methanol. Afterwards, samples were heated in
citrate acid (pressure cooker, pH 6.0, 5 minutes) and washed
in PBS. Blocking reagent and then the primary antibody were
added, followed by the biotinylated anti-mouse secondary anti-
body. After another washing step in PBS, slides were treated
with avidin-biotin complex for 30 minutes. Staining was done
with 3,3'-diaminobenzidin and counterstaining with hemalaun.
Fixated TMA slides were evaluated by bright field microscopy.
At least 100 cells per view were counted. HER2 expression
was scored semi-quantitatively using the 0 to 3+ score, follow-
ing common criteria [26]. In short, absence of staining is
scored 0, 1+ indicates the lowest level of detectable staining
(<10%) or inhomogeneous weak staining, 2+ moderate
homogeneous membrane staining, and 3+ intense homogene-
ous membrane staining. All 2+ and 3+ cases were regarded
as positive.
As positive nuclear staining was homogenous, evaluation of
Top IIa, KI 67 and p53 expression was done according to the
percentage of positively stained cells only, regardless of the
intensity. For statistical evaluation, the median of all staining
results (in%) was determined and dichotomisation was com-
pleted according to this value.
Fluorescence in situ hybridization
FISH analysis was done with the PathVision Probe (Vysis Inc.,
Downers Grove, IL, USA), according to the manufacturer's
protocol. TMA slides were deparaffinized, dried, and placedBreast Cancer Research    Vol 7 No 6    Schindlbeck et al.
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into pretreatment buffer (2 × SSC, pH 7, 80°C, 30 minutes).
Next, the TMA slides were digested with protease (37°C, 90
minutes). After fixation and denaturation (70% formamide/2 ×
SSC, pH 7.0 to 8.0), hybridization with fluorescent-labeled
probes for the HER2 gene and alpha-satellite DNA for chro-
mosome 17 was done at 73°C for 2 minutes and at 37°C over-
night. The slides were washed, counterstained with 4'-6'-
diamidino-2'-phenylindole (DAPI II) and embedded. For later
fluorescence microscopy, slides were stored at -20°C and
kept dark. Fluorescence microscopy was carried out with the
Zeiss Axioscope/Zeiss Axiocam and AxioVision software (Carl
Zeiss, Oberkochen, Germany). Signals of at least 60 cells in
three different areas of the tumors were counted. Amplification
was evaluated with a ratio between HER2 and centromere
chromosome 17 signals equaling 2.0 or higher [26].
Statistics
A compilation of patient data and the results of BM and TMA
examinations were stored in an Excel database (Microsoft
Corp., Redmond, WA, USA). Statistical evaluation was per-
formed with the software SPSS 12.0 (SPSS Inc., Chicago, IL,
USA). The χ2 test and correlation analysis was used to com-
pare immunocytochemical, IHC and patient characteristics.
The dependence of disease free survival (DFS), distant dis-
ease free survival (DDFS) and overall survival (OS) on the
examined factors was calculated by Kaplan-Meier analysis
(log-rank test, univariate), and cox regression analysis (multi-
variate, inclusion stepwise forward).
Results
Patient characteristics and histological parameters
Bone marrow aspirates and TMAs of 265 patients were ana-
lyzed in this study. The median age of patients was 57 years
(31 to 88), 82 patients (31%) being premenopausal and 183
(69%) postmenopausal. Of the 265 patients, 153 patients
(58%) presented with pT1 tumors, 81 with pT2 (30.5%), 5
with pT3 (2%), 12 with pT4 (4.5%), and 14 were not classified
(5%). Additionally, 122 (46%) patients had lymph node metas-
tases at the time of primary surgery, 136 (51%) were negative,
and data for 7 patients were missing. The tumors of 232
patients were graded, of which 21 (9%) were classified as G1,
128 (55%) as G2, and 83 (36%) as G3. The distribution of
estrogen receptor, lymphangiosis and hemangiosis together
with other factors is shown in Table 2.
Comparing histological parameters with each other, tumor
size correlated significantly with lymph node involvement (p <
0.001), grading (p < 0.001) and lymphangiosis (p < 0.001),
and lymph node metastasis correlated with grading (p =
0.001), estrogen receptor negativity (p < 0.001), and lymph-
and hemangiosis (p < .001 each). Estrogen receptor negativ-
ity correlated with lymph- and hemangiosis (p < 0.001 each),
and lymphangiosis correlated with hemangiosis (p < 0.001).
As this was a retrospective study, patients received adjuvant
treatment according to former recommendations. Of the 265
patients, 139 had no adjuvant therapy at all, making them a
very interesting subgroup for following the 'natural course of
the disease'. Seventy patients had adjuvant chemotherapy,
regimens consisting of CMF (thirty-one patients), anthracyclin
containing combinations (twenty-one patients), anthracyclin/
taxane combination (ten patients) and taxanes in other combi-
nations (three patients). For five patients, chemotherapy was
not classified. Forty-eight patients received antihormonal treat-
ment. No data about adjuvant therapy were given for eight
patients.
Bone marrow
Of all the 265 patients whose BM status was known, 68
(25.7%) showed DTC-BM with a median of 2/2 × 106
screened cells (1 to 1,500). BM status did not correlate signif-
icantly with any of the examined histological factors (Table 2),
yet there was a trend that patients with a tumor size of more
than 2 cm (p = 0.06) and HER2 FISH positive tumors (p =
0.06) had a higher risk of hematogenous dissemination. HER2
IHC, Top IIa, Ki 67 or p53 did not predict the detection of
DTC-BM.
HER2 immunohistochemistry and fluorescence in situ 
hybridization
Altogether, 167 tumors could be evaluated for HER2 IHC. Of
these, 81 tumors were scored 0 (48.5%), 52 (31.1%) 1+, 19
(11.4%) 2+, and 15 (9.0%) 3+. In summary, 132 (71%)
tumors were HER2 negative (0, 1+), and 35 (21%) positive
Table 1
Antibodies used for immunohistochemical staining
Factor Antibody Companya Dilution Scoring Cutoff
HER2 NCL-CB 11 Novocastra 1:40 0, 1, 2, 3 ≥ 2+
Top IIa Ab1, clone SWT3D1 Oncogene 1:40 % stained cells >10%
Ki 67 Ki 67, clone MIB-1 Dako 1:100 % stained cells >0%
p53 p53, clone DO-7 Dako 1:200 % stained cells >5%
HER2, human epithelial growth factor receptor 2; Top IIa, topoisomerase IIα.
aNovocastra, Newcastle upon Tyne, UK; Oncogene, Cambridge, MA, USA; DAKO, Hamburg, GermanyAvailable online http://breast-cancer-research.com/content/7/6/R1174
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(2+, 3+). HER2 IHC positivity was not correlated with the
standard histological markers or DTC-BM, but correlated
strongly with hemangiosis (p = 0.01), and expression of Top
IIa (p = 0.06), Ki 67 (p = 0.031), and p53 (p < 0.001). Looking
at patients with HER2 3+ positive tumors only, there was cor-
relation with estrogen receptor negativity (p = 0.009), Top IIa
(p = 0.004) and p53 (p = 0.014), but not to other factors.
In the FISH analysis, 121 tumors (75.7%) showed no HER2
amplification, 39 were positive (24.3%) with an amplification
(ratio HER2/centromer enumeration probe 17) ≥ 2. Compared
to IHC, 10/72 (13.9%) cases graded 0, 9/46 (19.5%) 1+
tumors, 7/16 (43.7%) 2+ and 10/15 (66.7%) 3+ cases were
amplified (Table 3). Correlation between IHC and FISH was
<0.001. HER2 amplification did not correlate statistically with
the other examined factors, but indicated a trend towards BM
positivity (p = 0.06).
Topoisomerase IIα
Overall, 187 tumors could be evaluated for Top IIa expression.
The median expression rate was 10% (0 to 90). Top IIa posi-
tivity (>10%, n = 87, 46%) was significantly correlated to
estrogen receptor negativity (p = 0.026), and Ki 67 (p =
0.002) and p53 expression (p < 0.001). Also, a trend for pos-
itivity was seen in HER2 IHC positive patients (p = 0.06). BM
status or other factors were not related to Top IIa.
Ki 67
Tumors of 184 patients could be evaluated for Ki 67, of which
52 (28.3%) showed positive staining (0% to 15%). Positivity
for Ki 67 (>0%) was correlated with estrogen receptor nega-
tivity (p = 0.034). Only 27.3% (36/132) of the Ki 67 negative
tumors, but 43.6% (24/55) of the Ki 67 positive ones, were
estrogen receptor negative. There also was significant corre-
lation between the expression of Ki 67 and p53 (p = 0.004).
P53
Tumors of 181 patients could be evaluated for p53 expres-
sion. Of these, 114 (63%) showed staining, with a median of
5% of the cells stained (0 to 100). Positivity of more than 5%
was seen in 61 cases (33.7%). Expression of p53 correlated
with HER2, Top IIa and Ki 67 expression as well as estrogen
receptor negativity (p = 0.03), but not with other histological
Table 2
Correlation of characteristics and histological parameters with bone marrow status
Characteristic or histological parameter No. of patients Patients (%) Correlation with BM status (p)
Menopause No 82 31 0.75
Yes 183 69
Tumor size <2 cm 153 61 0.06
≥2 cm 98 39
na 14
Lymph node involvement No 136 53 0.29
Yes 122 47
na 7
Grading 1, 2 149 64 0.65
38 3 3 6
na 33
Estrogen receptor Positive 141 60 0.85
Negative 94 40
na 30
Lymphangiosis No 196 75 0.38
Yes 64 25
na 5
Hemangiosis No 245 95 0.58
Yes 12 5
na 8
BM, bone marrow; na, not available.Breast Cancer Research    Vol 7 No 6    Schindlbeck et al.
R1179
parameters or DTC-BM. For all of the correlations between
factors see Table 4.
Disease free survival
Median observation time of all the patients was 60.5 months
(7 to 255). Patients revealing tumor recurrence, metastases,
or tumor associated death within six months after BM aspira-
tion have been excluded from follow-up analysis (n = 8). Of the
remaining 257 cases, 88 exhibited tumor recurrence (34%),
70 had distant metastases (27%), 18 showed only local
recurrence, and 26 showed both local and distant recurrence.
As could be expected, tumor size >2 cm (p < 0.001), lymph
node involvement (p < 0.001), grading (G3, p = 0.006), lym-
phangiosis (p < 0.001), and hemangiosis (p < 0.001) all sig-
nificantly indicated shortened DFS. This was not seen for
estrogen receptor negativity (p = 0.52) or the presence of
DTC-BM (p = 0.36). Of all the examined stainings, HER2 pos-
itivity significantly indicated shortened DFS, both in IHC (p =
0.04; Fig. 1) and FISH (p = 0.03). This was not demonstrated
for the HER2 3+ cases only. Also, positive Ki 67 staining was
significant for shortened DFS (p = 0.04).
Looking at subgroups of patients in relation to adjuvant ther-
apy, none of the examined factors could significantly predict
DFS in the group of patients who underwent chemo- or
antihormonal therapy. This was different in the group of
patients receiving no adjuvant therapy (n = 138). Again, HER2
IHC (p < 0.001), HER2 FISH (p = 0.003), and Ki 67 positivity
(p = 0.008) were significant prognostic factors for reduced
DFS.
In multivariate analysis (cox-regression), only tumor size (p =
0.001) and lymphangiosis (p = 0.003) were independent
prognostic factors for DFS with a relative risk of 2.2 and 2.1
for tumor recurrence.
Distant disease free survival
Of the 257 patients, 70 developed distant metastases during
the observation period. Again, tumor size (p < 0.001), lymph
node involvement (p < 0.001), grading 3 (p = 0.003), lym-
phangiosis (p < 0.001), and hemangiosis (p < 0.001) may sig-
nificantly predict the later development of distant metastases.
This was not seen for estrogen receptor negativity (p = 0.57).
The presence of DTC-BM indicated a trend towards reduced
DDFS, but was not significant in this population (p = 0.09). Of
the tumor biological factors, HER2 IHC (p = 0.06) and FISH
(p = 0.05) also were at the border of significance, whereas Ki
67 positivity again showed a trend towards shortened DDFS
(p = 0.09).
In the subgroup of patients receiving chemotherapy, none of
the factors was significant for DDFS. In patients receiving hor-
monal treatment, p53 positivity predicted shortened DDFS (p
= 0.023).
In the subgroup not receiving adjuvant treatment, again HER2
IHC (p = 0.003), HER2 FISH (p < 0.001), and Ki 67 (p =
0.02) positivity significantly indicated shortened DDFS.
In multivariate analysis, only tumor size (p = 0.003) and lym-
phangiosis (p < 0.001) independently predicted reduced
DDFS with a relative risk of 2.2 and 2.7 for the development of
metastases.
Overall survival
During the follow up period, 55 patients (21.4%) died
because of tumor associated reasons. As could be expected,
tumor size (>2 cm), lymph node involvement, grading 3, lym-
phangiosis and hemangiosis all predicted reduced OS (p <
0.001 each). For OS, the presence of DTC-BM also was sig-
nificant (p = 0.03; Fig. 2). Of the 188 patients without pres-
ence of DTC-BM, 34 (18%) died because of tumor associated
reasons, compared to 21 of 69 patients (30.4%) with positive
Table 3
Distribution of HER2 immunohistochemistry and fluorescence in situ hybridization
HER2 IHC HER2 amplification No. of cases % FISH positive
0N e g a t i v e 6 2
Positive 10 13.9
1+ Negative 37
Positive 9 19.5
2+ Negative 9
Positive 7 43.7
3+ Negative 5
Positive 10 66.7
Correlation p < 0.001. FISH = fluorescence in situ hybridization; HER2 = human epithelial growth factor receptor 2; IHC = 
immunohistochemistry.Available online http://breast-cancer-research.com/content/7/6/R1174
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BM status. Of the 55 patients who died from the disease, 21
(38%) had DTC-BM, compared to only 48 of the 202 patients
(24%) who were still alive. Such a correlation was not demon-
strated for HER2, Top IIa, Ki 67 or p53. Even for patients with
HER2 3+ tumors, OS was not reduced statistically. Looking at
subgroups, DTC-BM were also significant in the cohort with
hormonal therapy (p = 0.04), whereas HER2 IHC (p = 0.04)
and FISH (p = 0.01) were significant in the patients without
adjuvant therapy (n = 138). In patients receiving
chemotherapy, none of the factors reached significance. The
prognostic significance of all the examined factors for OS,
DFS, and DDFS is listed in Table 5.
In multivariate analysis, again only tumor size and lymphangio-
sis remained as independent prognostic factors for OS (p <
0.001 each), with a relative risk of tumor associated death of
3.8 and 2.9, respectively.
Discussion
Despite the extended use of systemic cytotoxic or hormonal
therapy in all stages of breast cancer, the search for factors to
discriminate between patients that will benefit most from sys-
temic treatments and for targets of tailored therapies is of
major importance. The detection of DTC-BM indicates hema-
togenous tumor cell spreading and has proved its prognostic
significance in many studies [3,5,6,27]. With these promising
insights, these cells could be an interesting marker for the sta-
tus of the disease and targeted therapies. With a prevalence
of DTC-BM in 25.7% of all patients and a median of 2 DTCs
per 2 × 106 screened cells (1 to 1,500), our results are in the
range of the reported findings [25]. In spite of this, there is little
knowledge on the biological behavior of these cells. It is not
quite clear which of the primary tumor's factors cause hema-
togenous spread, which factors are inherited by circulating
tumor cells in blood or BM, which factors have to be lost, and
which are needed for the later development of distant metas-
tases. As shown, the genetic structure of primary tumors from
patients with DTC-BM is different from those of BM negative
ones in terms of extracellular matrix modeling, signal transduc-
tion, adhesion or angiogenesis factors [28]. To further under-
stand these processes, we looked at the biological factors of
tumors from 265 patients with known BM status at the time of
primary diagnosis. Staining and hybridization was performed
on TMAs of the primary tumors. The tumor TMA technology is
a rapid, high throughput survey method to pinpoint molecular
markers for detailed studies with conventional tissue speci-
mens. Although TMAs were evaluated by a pathologist for
H&E staining, a possible limitation is that the samples acquired
from the original tissues, in light of intratumor heterogeneity,
may not always be representative of the entire tumor. Method-
ical problems, mainly the bad quality of older tissue speci-
mens, reduced the number of cases that could be evaluated
by up to 30%. Despite differences in IHC staining, evaluation
and cutoffs used for statistical analysis, however, expression
rates of the investigated factors can be compared to those
reported with conventional tissue slides.
Twenty to forty percent of breast carcinomas show mutations
of the TP53 gene. In our collection, 114 of 181 stained sam-
ples (63%) showed expression of a mutated p53 protein,
although the intensity of staining was very weak (median 5%
of cells, 0 to 100). Using the cutoff of at least 5% stained cells,
Table 4
Correlation of histological and tumor biological factors
p-value
Tumor size LN pos G = 3 ER LA HA BM HER2 HER2F Top IIa Ki67 p53
Tumor size - <0.001 <0.001 0.50 <0.001 0.053 0.063 0.50 0.31 0.09 0.61 0.44
LN pos <0.001 - 0.001 <0.001 <0.001 <0.001 0.29 0.47 0.17 0.16 0.17 0.45
G = 3 <0.001 0.001 - 0.10 0.001 0.90 0.65 0.11 0.8 0.71 0.80 0.17
ER neg 0.50 <0.001 0.10 - <0.001 <0.001 0.85 0.29 0.12 0.026 0.034 0.03
LA <0.001 <0.001 0.001 <0.001 - <0.001 0.38 0.64 0.57 0.441 0.36 0.98
HA 0.053 <0.001 0.90 <0.001 <0.001 - 0.58 0.01 0.66 0.89 0.87 0.39
BM 0.063 0.29 0.65 0.85 0.38 0.58 - 0.82 0.063 0.47 0.86 0.67
HER2 0.50 0.47 0.11 0.29 0.64 0.01 0.82 - <0.001 0.06 0.031 <0.001
HER2F 0.31 0.17 0.80 0.12 0.57 0.66 0.063 <0.001 - 0.45 0.55 0.35
Top IIa 0.09 0.16 0.71 0.026 0.441 0.89 0.47 0.06 0.45 - 0.002 <0.001
Ki67 0.61 0.17 0.80 0.034 0.36 0.87 0.86 0.031 0.55 0.002 - 0.004
P53 0.44 0.45 0.17 0.03 0.98 0.39 0.67 <0.001 0.35 <0.001 0.004 -
BM, bone marrow; ER, estrogen receptor; HA, hemangiosis; HER2 = human epithelial growth factor receptor 2; HER2F, HER2 FISH; LA, 
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p53 positivity (33.7%) correlated significantly with Ki 67 (p =
0.004), Her2 (p < 0.001), Top IIa (p < 0.001) and estrogen
receptor negativity (p = 0.03), which is in accordance with
reported findings [29,30]. There was no correlation with the
presence of DTC-BM, even if we used a cutoff of 10% of the
stained cells, as suggested by others [31]. p53 could not
statistically predict DFS, DDFS or OS; the only significance
was found for DDFS (p = 0.023) in patients receiving hormo-
nal therapy. This is in contrast to reported findings, where p53
was a significant prognostic marker [32,33]. Yet, there is still
controversy about the most suitable method for determining
p53 status, and molecular methods seem to be superior to
IHC [12,34,35].
Staining for Ki 67 was evident in 52 of 184 cases (28.3%),
which in median was very weak. This is in accordance with
similar studies [36], although higher cutoffs of positive staining
have been used by others [37]. Again, there was significant
correlation of Ki 67 staining with the examined biological fac-
tors and estrogen receptor negativity (p = 0.03), but not with
Figure 1
Correlation of disease free survival (DFS) with HER2 immunohistochemistry (IHC) results Correlation of disease free survival (DFS) with HER2 immunohistochemistry (IHC) results. Cum, cumulative; neg, negative; pos, positive.
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DTC-BM. In a study by Fehm et al. [38] examining the correla-
tion between Ki 67 and the presence of DTC-BM, the elevated
proliferation index significantly predicted the presence of
DTC-BM. In our study, Ki 67 positivity was not related to OS,
but indicated a trend towards shortened DFS (p = 0.07) and
DDFS (p = 0.09) for all patients. In subgroups of patients,
those without adjuvant therapy and Ki 67 positive tumors had
significantly reduced DFS (p = 0.008) and DDFS (p = 0.06).
This confirms findings published by many others [39].
Top IIa expression occurred in 163 of 181 tumors (90%), with
a median of 10% positive cells (0% to 90%). This median,
which was used as cutoff, has also been described by others
[40]. Again, there was no correlation between Top IIa expres-
sion and DTC-BM. Top IIa supports DNA decoiling, chromo-
some segregation during the anaphase of the cell cycle, and
DNA replication [41]. Overexpression of Top IIa has predictive
value for the effectiveness of therapies involving topoisomer-
ase inhibitors such as anthracyclines. The dependence of
anthracyclin chemosensitivity or resistance on the level of Top
IIa expression has been shown in vitro as well as in clinical
studies [42,43]. In a recently published study, Top IIa positivity
showed a trend towards prolonged DFS after anthracyclin
therapy and reduction of DTC-BM [44]. In this study, neither
Figure 2
Correlation of overall survival with bone marrow (BM) status (Kaplan-Meier analysis, logrank-test) Correlation of overall survival with bone marrow (BM) status (Kaplan-Meier analysis, logrank-test). Cum, cumulative; DTC-BM = DTCs in bone mar-
row; neg, negative; pos, positive.
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DFS, DDFS nor OS were related to Top IIa positivity, not even
in the subgroup of patients receiving anthracyclin based
chemotherapy. The most obvious reason is probably the het-
erogeneity of the collective, which consisted of small
subgroups.
Regarding therapeutic consequences, the most prominent
tumor biological factor now is HER2. With a positivity rate of
21% in IHC and 24.3% in FISH, we are within the range of
reported findings [45,46]. As expected, there was strong cor-
relation between HER2 amplification and protein expression
(p < 0.001), but 66.7% of FISH positive cases in the IHC 3+
group was rather low compared to other studies [47]. Discrep-
ancies between both methods might be due, in part, to bad tis-
sue quality and problems with FISH analysis of older paraffin
embedded tissue specimens. There was no relation of HER2
IHC positivity with the detection of DTC-BM, which confirms
our former results in a different patient population [48]. Yet,
HER2 amplification in FISH showed a trend towards BM pos-
itivity (p = 0.06), as was seen in a study by Naume et al. [49]
showing a more frequent detection of DTC-BM in HER2 pos-
itive patients. Despite intensive research in this field, the prog-
nostic impact of HER2 is still under discussion [50]. In our
collective, HER2 positivity was a significant prognostic factor
for DDFS and DFS, especially in patients receiving no adjuvant
therapy. In this subgroup, HER2 positivity also predicted
reduced OS. HER2 seems, however, to be rather a predictive
factor for the effectiveness of different chemotherapies,
including trastuzumab [22].
Conclusion
Tumorigenesis and dissemination are complex multistep proc-
esses. The prognostic value of individual biological factors
could, therefore, be more effective in combination as opposed
to single factors, which has been demonstrated in several
studies [51,52]. For this reason, we analyzed the correlations
of different factors with each other. The congruence of the
expression rates of the examined tumor biological factors indi-
cates a causal line of suppressor, proliferation and mitosis
markers and growth factor receptors. Although targeting of
single factors could demonstrate therapeutic efficacy, block-
ing several steps of tumor cell metabolism might be even more
effective. Hematogenous tumor cell spread, however, seems
to be rather an independent process. The examination of such
different factors on DTC-BM themselves is the aim of ongoing
research. The combination of the prognostic impact of DTC-
BM and both the prognostic and predictive value of tumor
biological factors could help to better stratify patients for indi-
vidual therapies. DTC-BM comprise a heterogenous 'pool' of
cells [7] differing from primary tumors in many ways. As DTC-
BM are in a dormant state [53], antimitotic chemotherapy in
general has little effect on them [54]. In contrast, antibody
based therapy against them is under investigation and has
shown promising results. Therapy against the epithelial plate-
let cell adhesion molecule (EPCAM) surface antigen showed
good results in reducing DTC-BM [55]. By determining the
HER2 status of circulating tumor cells, Meng et al. [56]
demonstrated astonishing results with trastuzumab therapy.
All these studies point to the potential of using DTC status for
the stratification of patients and targeting for tailored thera-
pies. This should be the basis of further research on the detec-
tion, enrichment and characterization of DTCs.
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